1100 13th Street, NW, Suite 1000Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2020The Kiplinger Washington Editors
Coronavirus fears have triggered volatility, a correction and ultimately a bear market in U.S. stocks in 2020. Many companies have suffered...
Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study
It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.
More Investing News »